CSPC Pharmaceutical Group Limited
0.98
EUR
-0.03
(-3.32%)
ISIN
HK1093012172
Return %
Stock
S&P 500
1Y
-0.09
14.20
3Y
48.02
81.12
5Y
5.52
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Lei Cai
- Full Time Employees
- 19,700
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 226 Huanghe Street Shijiazhuang HE China 050035
- IPO Date
- Jun 21, 1994
- Website
- cspc.com.hk
- Similar Companies
- Business
- CSPC Pharmaceutical Group Limited (1093.HK), an investment holding company founded in 1992 and headquartered in Shijiazhuang, Hebei Province, People's Republic of China, researches, develops, manufactures and sells pharmaceutical products primarily in Mainland China, other Asian regions, Europe, North America and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments; Finished Drugs include innovative products such as NBP soft capsules and injections for acute ischemic stroke, Oulaining capsules and lyophilised powder for injections to treat mild to moderate memory and mental impairment, Enxi for adult idiopathic Parkinson’s disease, Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers and other malignant tumors, Jinyouli to prevent leucopenia and infection induced by chemotherapy, Keaili for breast cancer, Xuanning for hypertension, Shuluoke, Nuomoling, Weihong and Xinweihong for various infections, Encun to prevent atherosclerotic thrombosis events, Qixiao for upper respiratory tract infection, Linmeixin and Shuanglexin for diabetes, Gubang and Gubangjia for osteoporosis in postmenopausal women, Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, low back pain, sprain, strain and other soft tissue injuries, Debixin for various ulcers and Qimaite for acute and chronic pains; Bulk Products encompass antibiotics such as penicillin G potassium salt, benzylpenicillin potassium and sodium, amoxicillin, ampicillin and sodium, cefazolin sodium, meropenem, biapenem and ertapenem, vitamin C and caffeine series active pharmaceutical ingredients; additional offerings comprise functional food products and healthcare services. Manufacturing facilities locate mainly in Shijiazhuang City, Hebei Province, supported by international R&D bases in Shijiazhuang, Shanghai, Beijing and the United States focusing on small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field across therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Recent developments feature a June 2025 strategic collaboration with AstraZeneca valued at US$110 million upfront for AI-driven discovery and development of novel oral drugs targeting immunological diseases building on a prior 2024 licensing agreement for metabolic disorders, a July 2025 global license agreement with Madrigal Pharmaceuticals for preclinical oral small molecule GLP-1 receptor agonist SYH2086 involving US$120 million upfront and up to US$2 billion in milestones plus royalties, and US clinical trial approval in November 2025 for double-stranded small interfering RNA drug SYH2061 injection; the company targets over 50 new product or indication submissions in the next five years while pursuing 1-2 annual out-licensing deals and integrating digital transformation including artificial intelligence in drug development.
Company News
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
AstraZeneca obesity tie-up with CSPC seen as shrewd move
CSPC Pharmaceutical Group (OTCMKTS:CSPCY) Shares Down 0.5% – Here’s What Happened